Dr Leonard Post takes position on Viralytics board
This article was originally published in Scrip
Eminent US virologist Dr Leonard Post has joined the board of directors of Viralytics, an Australian biotech company, as a non-executive director. Dr Post was previously a director and consultant of Biovex, which was recently acquired by Amgen, as well as chief scientific officer of LEAD Therapeutics. He is currently CSO of BioMarin Pharmaceuticals, and also an advisor to CM Capital, a director of two US-based biotech companies and a member of several scientific advisory boards.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.